FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2783107229> ?p ?o ?g. }

• W2783107229 endingPage "1299" @default.
• W2783107229 startingPage "1292" @default.
• W2783107229 abstract "Objective To assess stroke/systemic embolism, major bleeding and other outcomes, and treatment effect of apixaban versus warfarin, in patients with atrial fibrillation (AF) and different types of valvular heart disease (VHD), using data from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial. Methods There were 14 793 patients with known VHD status, categorised as having moderate or severe mitral regurgitation (MR) (n=3382), aortic regurgitation (AR) (n=842) or aortic stenosis (AS) (n=324); patients with moderate or severe mitral stenosis were excluded from the trial. Baseline characteristics, efficacy and safety outcomes were compared between each type and no significant VHD. Treatment effect was assessed using an adjusted model. Results Patients with MR or AR had similar rates of stroke/systemic embolism and bleeding compared with patients without MR or AR, respectively. Patients with AS had significantly higher event rates (presented as rate per 100 patient-years of follow-up) of stroke/systemic embolism (3.47 vs 1.36; adjusted HR (adjHR) 2.21, 95% CI 1.35 to 3.63), death (8.30 vs 3.53; adjHR 1.92, 95% CI 1.41 to 2.61), major bleeding (5.31 vs 2.53; adjHR 1.80, 95% CI 1.19 to 2.75) and intracranial bleeding (1.29 vs 0.51; adjHR 2.54, 95% CI 1.08 to 5.96) than patients without AS. The superiority of apixaban over warfarin on stroke/systemic embolism was similar in patients with versus without MR (HR 0.69, 95% CI 0.46 to 1.04 vs HR 0.79, 95% CI 0.63 to 1.00; interaction P value 0.52), with versus without AR (HR 0.57, 95% CI 0.27 to 1.20 vs HR 0.78, 95% CI 0.63 to 0.96; interaction P value 0.52), and with versus without AS (HR 0.44, 95% CI 0.17 to 1.13 vs HR 0.79, 95% CI 0.64 to 0.97; interaction P value 0.19). For each of the primary and secondary efficacy and safety outcomes, there was no evidence of a different effect of apixaban over warfarin in patients with any VHD subcategory. Conclusions In anticoagulated patients with AF, AS is associated with a higher risk of stroke/systemic embolism, bleeding and death. The efficacy and safety benefits of apixaban compared with warfarin were consistent, regardless of presence of MR, AR or AS. Clinical trial registration ARISTOTLE clinical trial number NCT00412984 ." @default.
• W2783107229 created "2018-01-26" @default.
• W2783107229 creator A5005079489 @default.
• W2783107229 creator A5007389891 @default.
• W2783107229 creator A5009790128 @default.
• W2783107229 creator A5014449865 @default.
• W2783107229 creator A5015603706 @default.
• W2783107229 creator A5041974328 @default.
• W2783107229 creator A5063591215 @default.
• W2783107229 creator A5067237537 @default.
• W2783107229 creator A5067347864 @default.
• W2783107229 creator A5080234509 @default.
• W2783107229 creator A5086287744 @default.
• W2783107229 creator A5087154648 @default.
• W2783107229 creator A5090233891 @default.
• W2783107229 date "2018-01-19" @default.
• W2783107229 modified "2023-10-17" @default.
• W2783107229 title "Outcomes in anticoagulated patients with atrial fibrillation and with mitral or aortic valve disease" @default.
• W2783107229 cites W1967104177 @default.
• W2783107229 cites W1974472268 @default.
• W2783107229 cites W1982544784 @default.
• W2783107229 cites W1989146257 @default.
• W2783107229 cites W1996669907 @default.
• W2783107229 cites W2004497902 @default.
• W2783107229 cites W2008616637 @default.
• W2783107229 cites W2016206445 @default.
• W2783107229 cites W2053887755 @default.
• W2783107229 cites W2092435752 @default.
• W2783107229 cites W2109155503 @default.
• W2783107229 cites W2112668676 @default.
• W2783107229 cites W2113470320 @default.
• W2783107229 cites W2118857793 @default.
• W2783107229 cites W2158604698 @default.
• W2783107229 cites W2162508946 @default.
• W2783107229 cites W2274286352 @default.
• W2783107229 cites W2281457724 @default.
• W2783107229 cites W2369150255 @default.
• W2783107229 cites W2511621035 @default.
• W2783107229 cites W2885325262 @default.
• W2783107229 cites W3004050106 @default.
• W2783107229 cites W905650230 @default.
• W2783107229 doi "https://doi.org/10.1136/heartjnl-2017-312272" @default.
• W2783107229 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29352007" @default.
• W2783107229 hasPublicationYear "2018" @default.
• W2783107229 type Work @default.
• W2783107229 sameAs 2783107229 @default.
• W2783107229 citedByCount "14" @default.
• W2783107229 countsByYear W27831072292018 @default.
• W2783107229 countsByYear W27831072292019 @default.
• W2783107229 countsByYear W27831072292020 @default.
• W2783107229 countsByYear W27831072292021 @default.
• W2783107229 countsByYear W27831072292022 @default.
• W2783107229 crossrefType "journal-article" @default.
• W2783107229 hasAuthorship W2783107229A5005079489 @default.
• W2783107229 hasAuthorship W2783107229A5007389891 @default.
• W2783107229 hasAuthorship W2783107229A5009790128 @default.
• W2783107229 hasAuthorship W2783107229A5014449865 @default.
• W2783107229 hasAuthorship W2783107229A5015603706 @default.
• W2783107229 hasAuthorship W2783107229A5041974328 @default.
• W2783107229 hasAuthorship W2783107229A5063591215 @default.
• W2783107229 hasAuthorship W2783107229A5067237537 @default.
• W2783107229 hasAuthorship W2783107229A5067347864 @default.
• W2783107229 hasAuthorship W2783107229A5080234509 @default.
• W2783107229 hasAuthorship W2783107229A5086287744 @default.
• W2783107229 hasAuthorship W2783107229A5087154648 @default.
• W2783107229 hasAuthorship W2783107229A5090233891 @default.
• W2783107229 hasConcept C126322002 @default.
• W2783107229 hasConcept C127413603 @default.
• W2783107229 hasConcept C164705383 @default.
• W2783107229 hasConcept C2776301958 @default.
• W2783107229 hasConcept C2777185221 @default.
• W2783107229 hasConcept C2777543888 @default.
• W2783107229 hasConcept C2778661090 @default.
• W2783107229 hasConcept C2779161974 @default.
• W2783107229 hasConcept C2779208316 @default.
• W2783107229 hasConcept C2779736815 @default.
• W2783107229 hasConcept C2780007028 @default.
• W2783107229 hasConcept C2780638905 @default.
• W2783107229 hasConcept C2780645631 @default.
• W2783107229 hasConcept C2993373945 @default.
• W2783107229 hasConcept C71924100 @default.
• W2783107229 hasConcept C78519656 @default.
• W2783107229 hasConceptScore W2783107229C126322002 @default.
• W2783107229 hasConceptScore W2783107229C127413603 @default.
• W2783107229 hasConceptScore W2783107229C164705383 @default.
• W2783107229 hasConceptScore W2783107229C2776301958 @default.
• W2783107229 hasConceptScore W2783107229C2777185221 @default.
• W2783107229 hasConceptScore W2783107229C2777543888 @default.
• W2783107229 hasConceptScore W2783107229C2778661090 @default.
• W2783107229 hasConceptScore W2783107229C2779161974 @default.
• W2783107229 hasConceptScore W2783107229C2779208316 @default.
• W2783107229 hasConceptScore W2783107229C2779736815 @default.
• W2783107229 hasConceptScore W2783107229C2780007028 @default.
• W2783107229 hasConceptScore W2783107229C2780638905 @default.
• W2783107229 hasConceptScore W2783107229C2780645631 @default.
• W2783107229 hasConceptScore W2783107229C2993373945 @default.
• W2783107229 hasConceptScore W2783107229C71924100 @default.
• W2783107229 hasConceptScore W2783107229C78519656 @default.

• next